EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Green Cross Corp (006280) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Green Cross Corp KRW 17,487, price KRW 123,300, upside -85.8%, quality 45 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · KR · ISIN KR7006280002

GC Thin data Sep 23, 2026

Green Cross Corp

006280 · KO

Structural break: The valuation model sees a lasting decline in earnings power for this stock, the confidence band is broken. Treat the target with caution.

Weakest SetupStrongly overvalued and low quality.

!Fair value 17,487 KRW · Strongly overvalued (−86%)
!Quality 45/100
!Mixed Growth (revenue 5y +5.8 %/yr)
!Loss-making · -0.7% net margin (TTM)
!Low debt · negative free cash flow
·1.22% dividend yield
!Trails peers (2/10)
!Narrow moat 21/100
!Evidence only low, so the estimate is less certain
!Weak on dividend: 24 out of 100
Watch Green Cross Corp for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

369,934 KRW 91,716 KRW Fair Value 17,487 KRW Apr 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

60‑month range 91,716 KRW – 369,934 KRW · fair‑value band 12,215 KRW – 22,164 KRW · the 123,300 KRW price screens above the 17,487 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 23, 2026.

Follow Green Cross in your weekly email

Every Wednesday you see whether Green Cross is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

GC Biopharma Corp., a biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea and internationally.

Show more

GC Biopharma Corp., a biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea and internationally. It provides over-the-counter drugs, such as Acustop Cataplasma for Analgesic and anti-inflammatory effect; Kenhancer plaster for anti-inflammatory; and Zenol Cool Type and Zenol Mild Hot Type drugs to treat anti-inflammatory and pain relief. The company also offers Albumin-GCC injection (inj.) for hypoalbuminemia and shock in acute hemorrhage, as well as low synthesis of albumin; Antithrombin-III (AT-III) inj. for hereditary antithrombin-III deficiency; Facnyne inj. for hemophilia B; Fibrinogen to treat hypofibrinogenemia and afibrinogenemia; Gamma Globulin for hypogammaglobulinemia and agammaglobulinemia; GCFLU Quadrivalent and GC FLU pre-filled syringe inj. for prevention of influenza; GreenGene F inj. for bleeding symptom control and hemostasis for persons with hemophilia A; GreenGene inj. for bleeding episodes induced by hemophilia A; Greenplast Q for sealing tissues and closing open wounds; and Green-VIII inj. for Hemophilia A with supplies of blood coagulation factor VIII. In addition, it provides Hepabig inj. for hepatitis B; Histobulin to treat bronchial asthma; Hunterase for hunter syndrome; I.V. Hepabig inj. for prevention of hepatitis B recurrence in patients following liver transplantation; I.V.-Globulin SN inj. 5%; Immuncell-LC to treat liver cancer; Sero-Tet inj. for prophylaxis of tetanus and the reduction of tetanus symptoms; Shinbaro for anti-inflammation, pain relief, and osteoarthritis; and Varicella Vaccin. It has a research and development agreement with Novelty Nobility to develop antibody-based therapeutics for geographic atrophy. The company was founded in 1967 and is headquartered in Yongin-Si, South Korea. GC Biopharma Corp. operates as a subsidiary of Green Cross Holdings Corporation.

Stock analysis

Green Cross Corp (006280) currently trades at 123,300 KRW, while our model-based Fair Value estimate is 17,487 KRW, implying the stock looks roughly 605.2% overvalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of 85,114 KRW per share, and 1 of the 6 models we run sit above the 123,300 KRW price.

Bear case: the Earnings-Based group reads lowest at 17,755 KRW, and 5 of the 6 models stay below the price. Evidence for this calculation is low.

Scenario range: 12,215 KRW (bear) to 22,164 KRW (bull), the price of 123,300 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Green Cross Corp reported revenue of 2.0T KRW in FY2025 versus 1.5T KRW in FY2021, a compound +6.7%/yr. Reported net income was −4.7B KRW in FY2025.

Key figures

Market cap 1.4T KRW (≈ $985M) · P/S ratio 0.71 · Dividend yield 1.2% · Net margin −0.2% · Return on equity −2.3% · Return on assets (EBIT) 2.2% · Operating margin 2.7% · Revenue (TTM) 2.0T KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).

What moves the price

The share trades about 31% below its 52-week high and 9% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −86%, 006280 screens richer than that median.

Fair Value models

Bear 12,215 KRW Fair Value 17,487 KRW Bull 22,164 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
EPV 12,409 KRW 17,755 KRW 22,507 KRW 73
ROIC Compounder 12,409 KRW 17,755 KRW 22,507 KRW 72
EV/EBITDA 126,374 KRW 174,460 KRW 222,547 KRW 67
All 6 models by family
Earnings-Based
EPV 12,409 KRW 17,755 KRW 22,507 KRW 73
Multiples
EV/EBIT 59,364 KRW 85,114 KRW 110,864 KRW 65
EV/EBITDA 126,374 KRW 174,460 KRW 222,547 KRW 67
EV/Revenue 37,250 KRW 60,879 KRW 84,508 KRW 52
Asset-Based
NCAV (Graham) 53,337 KRW 71,471 KRW 106,673 KRW 54
Economic Profit
ROIC Compounder 12,409 KRW 17,755 KRW 22,507 KRW 72

Open the full fair value analysis →

Notify me when 006280 reaches fair value

Put 006280 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 45/100

Of which business quality 43 · Market factors (momentum, volatility) 35

Profitability 25
Margins and returns on capital today
Quality Growth 51
Are margins and returns improving?
Cashflow 15
Earnings quality: real cash, not paper profit
Fin. Strength 34
Balance sheet, leverage, solvency risk
Investment 85
Disciplined investing over empire-building
Low Volatility 55
Calm price path (market factor)
Momentum 30
Price trend over the last 3–12 months (market factor)
52W Momentum 22
Distance to the 52-week high (market factor)
Net Issuance 82
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 17/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+18.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.8%
Start year 2020 (pandemic). Over 10 years: +6.6% a year
Revenue growth 22 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
3.3% (2020) → 3.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

006280 screens 605% overvalued. Compare with Merck KGaA →

Compare Green Cross Corp with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 612 stocks

Beats the industry median on 2/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 45 · Below median
Fair Value upside −86% · Bottom 25%
Profitability
Return on assets 2% · Below median
Net margin (TTM) −1% · Below median
Operating margin (TTM) 3% · Below median
Growth and dividend
Revenue growth 14% · Above median
Dividend yield (TTM) 1.2% · Below median
Balance sheet
Debt / equity 0.21× · Above median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

EV/EBITDA 1.3× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 12
FUTURE (revenue growth)68 · sector 21
PAST (return on equity)0 · sector 25
HEALTH (low debt)90 · sector 96
DIVIDEND (yield)24 · sector 30

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €133.15 €108.70 −18%
Takeda Pharmaceutical Company TAK $18.95 $11.29 −40%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥45.72 ¥50.29 +10%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,846 ₹1,979 +7%
Galderma Group GALD CHF 163.80 CHF 109.88 −33%
Haleon plc HLN $9.25 $8.50 −8%
Teva Pharmaceutical Industries Limited TEVA $39.52 $20.75 −47%
Sandoz Group SDZ CHF 70.76 CHF 40.16 −43%
Zoetis Inc ZTS $72.86 $108.48 +49%
Hansoh Pharmaceutical Group 3692 HK$35.34 HK$38.87 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Green Cross Corp · Fair Value
17,487 KRW −605%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Green Cross Corp Fair Value". https://www.fairvalue-calculator.com/stock/006280

Frequently asked questions

Is Green Cross Corp (006280) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of 17,487 KRW versus a price of 123,300 KRW, about −86% upside (overvalued).
What is the fair value of 006280?
Our model-based fair value for Green Cross Corp is 17,487 KRW (as of Sep 23, 2026), built from audited fundamentals. The current price: 123,300 KRW.
What is the quality score of 006280?
Green Cross Corp has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Green Cross Corp (006280)?
Our model-based price target is the fair value of 17,487 KRW (as of Sep 23, 2026) from 6 valuation models. Cautious scenario 12,215 KRW, optimistic scenario 22,164 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Green Cross Corp stock forecast for 2026?
Our models put fair value at 17,487 KRW, about −86% upside versus a price of 123,300 KRW (overvalued). Cautious scenario 12,215 KRW, optimistic scenario 22,164 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Green Cross Corp (006280)?
Green Cross Corp reported trailing-twelve-month revenue of about 2.0T KRW (latest available figure, as of Sep 23, 2026).
Does Green Cross Corp pay a dividend?
Green Cross Corp currently shows a dividend yield of about 1.22% relative to its recent price (as of Sep 23, 2026).
What is the intrinsic value of Green Cross Corp (006280)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Green Cross Corp it is 17,487 KRW per share (as of Sep 23, 2026), against a price of 123,300 KRW. It is the blended result of 6 valuation models (cash flow, earnings, asset, dividend).
Is Green Cross Corp stock overvalued or undervalued in 2026?
As of Sep 23, 2026, 006280 trades above its calculated fair value: price 123,300 KRW, fair value 17,487 KRW, a gap of about −86% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 006280?
No. The price is what the market pays today (123,300 KRW); the fair value is what the company's own numbers justify (17,487 KRW). For Green Cross Corp the two are 105,813 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Green Cross Corp worth?
The market values Green Cross Corp at about 1.4T KRW (market capitalisation, as of Sep 23, 2026). Per share that is 123,300 KRW; our models calculate a fair value of 17,487 KRW per share.
What do the bullish and bearish scenarios say about 006280?
Our models span a range for Green Cross Corp: cautious scenario 12,215 KRW, base 17,487 KRW, optimistic 22,164 KRW per share (as of Sep 23, 2026, price 123,300 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Green Cross Corp (006280)?
Balance-sheet figures for Green Cross Corp (as of Sep 23, 2026): return on equity −2.3%, debt of 0.21 per unit of equity. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is 006280 from its 52-week high?
Green Cross Corp trades at 123,300 KRW, about 31% below its 52-week high of 178,509 KRW and 9% above the low of 113,300 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 17,487 KRW is for.
Which stocks are comparable to Green Cross Corp?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Green Cross Corp stock attractive at the current price?
The data as of Sep 23, 2026: price 123,300 KRW, calculated fair value 17,487 KRW (−86%), Quality Score 45/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 006280 calculated?
We run Green Cross Corp through 6 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 17,487 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Green Cross Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Green Cross Corp (006280)?
The closing price on Sep 23, 2026 was 123,300 KRW. Our model-based fair value is 17,487 KRW, about −86% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Green Cross Corp right now?
The price sits above even our optimistic bull case (22,164 KRW). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (45/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (12,215 KRW to 22,164 KRW) leaves room in how you read the outcome.

Key figures of Green Cross Corp

How large is the market capitalisation of Green Cross Corp (006280)?
The market capitalisation of Green Cross Corp is 1.4T KRW (≈ $985M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Green Cross Corp (006280)?
The price-to-sales ratio of Green Cross Corp is 0.71 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Green Cross Corp (006280)?
The dividend yield of Green Cross Corp is 1.2%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Green Cross Corp (006280)?
The net margin of Green Cross Corp is −0.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Green Cross Corp (006280)?
The return on equity (ROE) of Green Cross Corp is −2.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Green Cross Corp (006280)?
On an EBIT basis the return on assets of Green Cross Corp is 2.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Green Cross Corp (006280)?
The operating margin of Green Cross Corp is 2.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Green Cross Corp (006280)?
Revenue at Green Cross Corp is growing +13.5% versus a year earlier (3y avg +5.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Green Cross Corp (006280)?
Earnings per share at Green Cross Corp are growing −31.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Green Cross Corp (006280) generate?
The free cash flow of Green Cross Corp is −5.8B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Green Cross Corp (006280) carry?
The net debt of Green Cross Corp is 813B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Green Cross Corp in the live analysis

One click puts Green Cross Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.